• Epidemiology & Risk Factors
    • Exclusively occurs in pts with Sickle Cell Disease (SCD). Leading cause of death in SCD.
    • Triggers: Infection (most common; esp. Mycoplasma, Chlamydia, Streptococcus pneumoniae, viruses), asthma exacerbation, vaso-occlusive crisis (VOC) of ribs/sternum causing hypoventilation/splinting, fat embolism from bone marrow necrosis.
      • Pathogens (e.g., Chlamydia, Mycoplasma) cause inflammation upregulates endothelial adhesion molecules increases RBC/WBC sequestration in lungs. c
    • Often presents 48-72 hours after admission for a painful VOC.
  • Clinical Features
    • Fever (>38.5°C).
    • Chest pain, shortness of breath, tachypnea, cough, wheezing.
    • Hypoxia/hypoxemia.
    • PE: Crackles, decreased breath sounds.
  • Diagnosis
    • Initial/Diagnostic Criteria: CXR demonstrating a new radiodense pulmonary infiltrate involving at least one complete lung segment, plus 1 new symptom (fever, hypoxia, tachypnea, chest pain).
    • Key Labs:
      • CBC w/ diff (drop in Hb, leukocytosis).
      • Blood and sputum cultures.
      • ABG (hypoxemia).
      • Blood type and crossmatch (crucial for potential transfusion).
    • Imaging: CXR. Consider CT chest if PE strongly suspected or CXR equivocal.
  • Differential Diagnostics
    • Pneumonia: Often the trigger for ACS, making differentiation difficult. Treat for both simultaneously.
    • Pulmonary Embolism (PE): Diff by lack of fever (usually) and classically clear CXR early in the course. CTPA if high clinical suspicion.
    • Vaso-occlusive Crisis (Rib/Sternum): Diff by clear CXR. Note: Rib VOC causes splinting/atelectasis, which rapidly progresses to ACS.
    • Asthma Exacerbation: Diff by diffuse wheezing without focal consolidations on CXR, though asthma can trigger ACS.
  • Management
    1. Supportive (First-line):
      • O2 Therapy: Target SpO2 >92%.
      • Analgesics: IV opiates for pain (careful to avoid excessive sedation hypoventilation).
      • IVF: Euvolemia is the goal. Avoid fluid overload, which can precipitate pulmonary edema and worsen ACS.
    2. Medical Therapy:
      • Empiric Broad-Spectrum Abx: Cephalosporin (e.g., Ceftriaxone) + Macrolide (e.g., Azithromycin) to cover typical and atypical organisms. c
      • Incentive Spirometry: Mandatory to prevent atelectasis and further sickling.
      • Bronchodilators: If concurrent wheezing or history of asthma.
    3. Transfusion (Target Hb 10 g/dL):
      • Simple PRBC Transfusion: For early/mild ACS, symptomatic anemia, or Hb dropping >1 g/dL from baseline.
      • Exchange Transfusion: For severe ACS (multilobar infiltrates, rapidly progressive disease, severe hypoxia/ARDS, or failure of simple transfusion). Rapidly reduces HbS % without increasing blood viscosity.
  • Complications
    • Acute Respiratory Distress Syndrome (ARDS) / Respiratory failure.
    • Chronic lung disease / Pulmonary hypertension (Cor pulmonale).
    • Neurologic complications (seizures, altered mental status) due to severe hypoxia.
    • Death.